**Loss of IL-10 signaling promotes IL-22 dependent host defenses against acute
Clostridioides difficile infection**

Emily S. Cribas¹, Joshua E. Denny¹, Jeffrey R. Maslanka¹, Michael C. Abt¹

¹Department of Microbiology, Perelman School of Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania, USA.

**Running title: Loss of IL-10 signaling promotes host immune defense against *C. difficile*
infection**

*CORRESPONDENCE: Michael Abt. Michael.abt@pennmedicine.upenn.edu; 215-898-0596 (P)

Abbreviations used: ^{HET}- heterozygous, p.i. – post infection, ASV – Amplicon Sequence Variant

Abstract

Infection with the bacterial pathogen *Clostridioides difficile* causes severe damage to the intestinal epithelium that elicits a robust inflammatory response. Markers of intestinal inflammation accurately predict clinical disease severity. However, determining the extent to which host-derived proinflammatory mediators drive pathogenesis versus promote host protective mechanisms remains elusive. In this report, we employed *Il10*^{-/-} mice as a model of spontaneous colitis to examine the impact of constitutive intestinal immune activation, independent of infection, on *C. difficile* disease pathogenesis. Upon *C. difficile* challenge, *Il10*^{-/-} mice exhibited significantly decreased morbidity and mortality compared to littermate *Il10* heterozygote (*Il10*^{HET}) control mice, despite a comparable *C. difficile* burden, innate immune response, and microbiota composition following infection. Similarly, antibody-mediated blockade of IL-10 signaling in wild-type C57BL/6 mice conveyed a survival advantage if initiated three weeks prior to infection. In contrast, no advantage was observed if blockade was initiated on the day of infection, suggesting that constitutive activation of inflammatory defense pathways prior to infection mediated host protection. IL-22, a cytokine critical in mounting a protective response against *C. difficile* infection, was elevated in the intestine of uninfected, antibiotic-treated *Il10*^{-/-} mice, and genetic ablation of the IL-22 signaling pathway in *Il10*^{-/-} mice negated the survival advantage following *C. difficile* challenge. Collectively, these data demonstrate that constitutive loss of IL-10 signaling, via genetic ablation or antibody blockade, enhances IL-22 dependent host defense mechanisms to limit *C. difficile* pathogenesis.

Introduction

Clostridioides difficile is a leading cause of nosocomial infections in the United States. High recurrence rates, increases in community-acquired infections, and the emergence of antibiotic-resistant strains render *C. difficile* an urgent threat to our public health system^{1–5}. The manifestation of *C. difficile* infection is highly variable; ranging from asymptomatic colonization, diarrhea, and pseudomembranous colitis, to severe cases of toxic megacolon and death⁶. Disease severity is shaped by the host immune response and patients on immunosuppressants or with autoimmune disorders are more susceptible to severe disease^{7–9}. Taken together, there is a need to study the host immune response to *C. difficile* infection to develop new therapies.

Upon intestinal colonization, *C. difficile* produces toxins that disrupt epithelial barrier integrity and result in translocation of commensal bacteria into submucosal tissues. Impaired barrier integrity leads to downstream induction of a multi-faceted, robust, inflammatory response^{10,11}. The innate immune response is essential for protection against *C. difficile* infection. Mice deficient in pathogen recognition receptor signaling pathways or innate immune cells exhibit increased bacterial translocation, damage to the epithelial barrier, and increased mortality following *C. difficile* infection^{12–16}. Conversely, proinflammatory mediators can simultaneously exacerbate tissue damage and promote *C. difficile* expansion to hinder recovery^{16–18}. In support of these animal studies, elevated fecal and serum proinflammatory cytokine levels are associated with increased disease severity in patients^{19–21}. Together, these findings highlight the complexity of the host response and demonstrate the need to fundamentally understand the timing and context of intestinal inflammation as a driver of *C. difficile* pathogenesis. To begin to address the contribution of the host proinflammatory immune response in promoting disease severity during *C. difficile* infection, elevated expression of intestinal inflammatory mediators was established in mice *a priori* *C. difficile* challenge and the disease severity following subsequent infection was investigated.

Interleukin-10 (IL-10) is a broad immunoregulatory cytokine that negatively regulates commensal bacteria-driven immune activation at steady-state^{22–24}. Intestinal expression of IL-10 is critical for maintaining intestinal homeostasis as mice deficient in the *Il10* gene develop microbiota-dependent spontaneous colitis characterized by chronic activation of inflammatory mediators that are also associated with *C. difficile* pathogenesis^{25–27}. Thus, *Il10*^{-/-} mice, a widely used model of intestinal immune dysregulation, offer the opportunity to decouple intestinal inflammation from infection to study the causative nature of inflammatory mediators in *C. difficile* pathogenesis²⁸.

In this report, we demonstrate that pre-existing intestinal immune activation, e.g. expression of proinflammatory cytokines driven by loss of IL-10 signaling, reduces susceptibility to *C. difficile* infection. Host protective immunity was independent of changes in *C. difficile* burden, toxin production, or the microbiota. The protective capacity of IL-10-deficient immune activation was dependent on IL-22 production enhancing early host defenses against *C. difficile* infection.

Results

IL-10 deficiency decreases susceptibility to acute *C. difficile* infection

At steady-state, IL-10 maintains intestinal homeostasis by negatively regulating commensal bacteria-driven expression of proinflammatory cytokines. In the context of *C. difficile* infection, many of these proinflammatory cytokines correlate with increased disease severity. However, it is unclear whether the inflammatory profile associated with infection emerges following *C. difficile*-mediated tissue damage or if it proactively drives pathology and worsens disease^{20,21}. To address this question, intestinal inflammation was induced independently of *C. difficile* infection using the murine *Il10*^{-/-} spontaneous colitis model and the impact of constitutive inflammation on *C. difficile* disease severity was examined. Cohoused *Il10*^{-/-} and littermate *Il10* heterozygous mice (*Il10*^{HET}) were treated with a broad-spectrum antibiotic cocktail in their drinking water to induce susceptibility to *C. difficile* and mimic the microbiota dysbiosis observed in patients at high risk for

contracting *C. difficile*. antibiotic-treated *Il10^{HET}* mice, exhibited peak disease severity within 48 hours of infection as measured by a disease score that measures weight loss, body temperature, diarrhea, and lethargy (Fig. 1A), and approximately 75% mortality rate (Fig. 1B). In contrast, *Il10^{-/-}* mice experienced reduced disease severity at 2 days post infection (p.i.) (Fig. 1A) and were less likely to succumb to acute *C. difficile* infection compared to *Il10^{HET}* mice (Fig. 1B).

Il10^{-/-} mice challenged with pathogenic *Escherichia coli*, *Salmonella typhimurium*, *Citrobacter rodentium*, *Toxoplasma gondii*, or *Candida albicans* all display improved pathogen clearance via enhanced phagocytic mechanisms by innate immune cells²⁹⁻³³. Thus, *C. difficile* burden was measured at day 1 and 2 p.i. No difference in *C. difficile* burden was observed in the cecal content of *Il10^{HET}* and *Il10^{-/-}* mice at days 1 (Fig. 1C) or 2 p.i. (Fig. 1D). Further, *C. difficile* toxin activity in the cecal content of *Il10^{HET}* and *Il10^{-/-}* mice was similar at day 2 p.i. as measured by an *in vitro* cell rounding assay (Fig. 1E). Together, these data indicate that loss of IL-10 augments host immunity following *C. difficile* infection but does not alter establishment of infection or production of toxins, the primary virulence factors of *C. difficile*.

Intestinal inflammation and subsequent onset of spontaneous colitis in *Il10^{-/-}* mice varies between vivaria and is dependent on the microbiota^{25,26}. To test the rigor of the observed phenotype in *C. difficile* infected *Il10^{-/-}* mice, complimentary experiments with cohoused wild-type C57BL/6 and *Il10^{-/-}* mice were conducted in an independent animal facility. In agreement with our studies in *Il10^{HET}* mice, *Il10^{-/-}* mice exhibited improved survival (Suppl. Fig. 1A) compared to cohoused C57BL/6 mice following *C. difficile* infection despite no difference in *C. difficile* burden (Suppl. Fig. 1B) or toxin production (Suppl. Fig. 1C), demonstrating the robustness of this phenotype.

Enhanced protection in *Il10^{-/-}* mice is not driven by a distinct microbiota composition

The composition of the microbiota impacts *C. difficile* pathogenesis through multiple direct and indirect mechanisms³⁴, therefore cohoused littermate mice were used to normalize for this

variable. To test the null hypothesis that the microbiota composition between *Il10*^{HET} and *Il10*^{-/-} mice was indistinguishable, bacterial 16S rRNA marker gene profiling was conducted on cecal content from *Il10*^{HET} and *Il10*^{-/-} mice collected at day 2 post *C. difficile* or mock infection. Microbial community alpha diversity was not different between uninfected or infected *Il10*^{HET} and *Il10*^{-/-} mice (Fig. 2A). Comparison of 16S rRNA bacterial community profiles between *Il10*^{HET} and *Il10*^{-/-} mice by relative bacterial abundance revealed a bloom of amplicon sequence variants (ASVs) identified as *C. difficile* in both *Il10*^{HET} and *Il10*^{-/-} infected mice compared to uninfected mice, however the relative abundance composition between infected groups was similar (Fig. 2B). Beta diversity comparisons between samples by unsupervised hierarchical clustering (Fig. 2C), unweighted UniFrac distances (Fig. 2D), or PERMANOVA analysis (Suppl. Table 1) did not lead us to reject the null hypothesis that there was no microbial community level differences between *Il10*^{HET} and *Il10*^{-/-} mice at day 2 following mock infection or *C. difficile* infection. A linear regression model was used to identify individual ASVs that correlate with *Il10*^{HET} and *Il10*^{-/-} phenotypes. The linear model readily detected *C. difficile* as significantly enriched in infected mice compared to uninfected mice but failed to identify an ASV significantly different between the microbiota of infected *Il10*^{HET} and *Il10*^{-/-} mice (Suppl. Fig. 2A,B).

In a validation cohort, 16S rRNA marker gene profiling was conducted on fecal pellets collected from C57BL/6 and *Il10*^{-/-} mice prior to cohousing (day -64 p.i.), throughout cohousing, the start of antibiotic treatment (day -6 p.i.), and on the day of infection (day 0 p.i.). Prior to cohousing, *Il10*^{-/-} mice exhibit a distinct microbiota (Suppl. Fig. 3A, Suppl. Table 2). Cohousing shifted the microbiota of C57BL/6 mice to resemble the microbiota of *Il10*^{-/-} mice as determined by unweighted UniFrac distance analysis (Suppl. Fig. 3A), relative bacterial genera abundance (Suppl. Fig. 3B), unsupervised hierarchical clustering (Suppl. Fig. 3C), and PERMANOVA analysis (Suppl. Table 2). Antibiotic treatment between day -6 and 0 p.i. significantly reduced the alpha diversity (Suppl. Fig. 3D) and shifted the microbiota of both C57BL/6 and *Il10*^{-/-} mice, but no difference between groups was observed (Suppl. Table 2). To identify specific ASVs that were

differentially abundant between cohoused C57BL/6 and *Il10*^{-/-} mice, a LEfSe comparison was conducted. Several ASVs were differentially abundant within the microbiota of C57BL/6 and *Il10*^{-/-} mice prior to cohousing (Suppl. Fig. 3E). However, following cohousing and antibiotic treatment, none of these differentially abundant ASVs remained (Suppl. Fig. 3E). Together, these microbial profiling data support the conclusion that the differential outcome observed in antibiotic-treated IL-10 sufficient and deficient hosts following *C. difficile* infection cannot be explained by community level differences in the microbiota.

***Il10*^{-/-} and *Il10*^{HET} mice exhibit comparable induction of innate immunity following *C. difficile* infection.**

No differences in *C. difficile* colonization, toxin production, or microbiota composition were observed between infected *Il10*^{HET} and *Il10*^{-/-} mice to account for enhanced protection in *Il10*^{-/-} mice, therefore potential immune-mediated mechanisms were assessed. Induction of IL-10 is an effective strategy employed by some enteric pathogens to dampen the host immune response to infection^{29,30,35–37}. *C. difficile*-derived flagellin, surface layer proteins, and toxin (TcdB) can all induce macrophages, monocytes, and dendritic cells to produce IL-10 *in vitro*^{38–40}. Indeed, C57BL/6 mice infected with *C. difficile* have elevated IL-10 protein in the cecal tissue at day 2 p.i. (Fig. 3A). The broad immunosuppressive functions of IL-10 include inhibition of granulocyte infiltration into mucosal tissue and limiting expression of type-1 and type-17 cytokines, components of the immune response that promote protective immunity following *C. difficile* infection^{41–43 44,45}. First protein levels of lipocalin-2 (LCN-2), an established marker of intestinal inflammation⁴⁶, were measured in the cecal content of antibiotic-treated uninfected and day 2 p.i. *Il10*^{-/-} and *Il10*^{HET} mice⁴⁶. LCN-2 levels increased to approximately the same concentration in both groups by day 2 p.i (Fig. 3B). To thoroughly assess the quality of the innate immune response to acute *C. difficile* infection, *Il10*^{-/-} and *Il10*^{HET} mice were sacrificed at day 2 p.i. and recruitment of innate immune cells and induction of proinflammatory cytokines were assessed. Both infected

Il10^{HET} and *Il10*^{-/-} mice exhibited a robust induction of the innate immune response compared to antibiotic-treated, uninfected, control mice (Fig. 3). However, no differences in the frequency (Suppl Fig. 4A,B) or total numbers of infiltrating neutrophils (Fig. 3C), monocytes (Fig. 3D), or eosinophils (Fig. 3E) were observed. *Il10*^{-/-} and *Il10*^{HET} mice at day 2 p.i. exhibited comparable elevated gene expression of *Ifng* and *Il22* (Fig. 3F) as well as downstream host defense genes *Nos2* and *Reg3g* in the colon (Fig. 3G). IFN- γ and IL-22 protein concentrations in cecal tissue homogenates were also comparable (Fig. 3H). Type-2 cytokines (IL-5, IL-13, IL-33) associated with eosinophil activation and protection during *C. difficile* infection^{15,38,39}, were not significantly different in the cecum *Il10*^{-/-} and *Il10*^{HET} mice at day 2 p.i. (Fig. 3I). Finally, no difference in proinflammatory cytokines (IL-1 β , IL-6, IL-17a, IL-27, GM-CSF) reported to modulate *C. difficile* pathogenesis^{16,40-44}, or chemokines (CXCL1, CXCL2, CCL2) involved in neutrophil and monocyte recruitment was observed in the cecal tissue homogenates of *Il10*^{-/-} and *Il10*^{HET} mice at day 2 p.i. (Suppl. Fig. 4C-D). Collectively, these data indicate the magnitude or quality of the innate immune response in *Il10*^{-/-} mice following *C. difficile* infection is not driving the attenuated disease phenotype.

Loss of IL-10 signaling prior to *C. difficile* infection drives immune activation in the intestine and augments protective immunity

In contrast to the comparable immune responses observed in *C. difficile* infected *Il10*^{-/-} and *Il10*^{HET} mice, antibiotic-treated uninfected *Il10*^{-/-} mice at day 2 post mock infection had higher levels of LCN-2 in the cecal content (Fig. 3B.) and increased expression of IL-22 and IFN- γ -dependent effector molecules (Fig. 3F) in the large intestine compared to antibiotic-treated uninfected *Il10*^{HET} mice. Moreover, antibiotic-treated *Il10*^{-/-} mice at day 0 p.i. displayed elevated immune activation in the large intestine compared to *Il10*^{HET} mice as determined by increased frequency (Fig. 4A) and total numbers (Fig. 4B) of infiltrating neutrophils in the large intestine as well as elevated

expression of proinflammatory immune defense genes (*Il22*, *Ifng*, *Reg3g*, *Nos2*) (Fig. 4C), as has been previously reported^{47,48}. These results support the hypothesis that pre-existing immune activation, not the magnitude of the immune response following infection, confers protective immunity in *Il10*^{-/-} mice.

To determine whether loss of IL-10 signaling prior to infection and subsequent immune activation augments protection following *C. difficile* infection, IL-10 signaling was selectively blocked in C57BL/6 mice starting either three weeks prior to infection or once on the day of infection and survival was assessed. Antibody-mediated blockade of the IL-10-specific receptor IL-10R1 (α IL10R1) administered once a week for at least 3 weeks abrogates IL-10 signaling and replicates the intestinal inflammation observed in germline *Il10*^{-/-} mice⁴⁹. C57BL/6 mice that received weekly α IL10R1 treatment starting 3 weeks prior to infection exhibited a comparable survival to *Il10*^{-/-} mice and significantly improved survival compared to C57BL/6 mice administered α IL10R1 at day 0 p.i. (Fig. 4D). These data support the hypothesis that IL-10 inhibits basal activation of intestinal immune defense genes prior to infection thereby rendering the host more susceptible to *C. difficile* infection.

IL-22 is critical for host defense against *C. difficile* infection in *Il10*^{-/-} mice

Inhibition of IL-10 signaling limits *C. difficile* pathogenesis only if initiated weeks prior to infection (Fig. 4D). Further, *Il10* deficiency leads to enhanced colonic *il22* and *ifng* expression in uninfected mice (Fig 4C). Both IL-22 and IFN- γ are critical in mounting a protective innate immune response during acute *C. difficile* infection^{13,14,50}. These observations suggest immune activation prior to infection promotes improved survival in *Il10*^{-/-} mice. To determine the relative contribution of these cytokine pathways to host protection in *Il10*^{-/-} mice, *Il22* or *Tbx21* (the gene that encodes T-bet, a master transcription factor that regulates IFN- γ production) was genetically ablated in *Il10*^{-/-} mice. Following *C. difficile* infection, *Il10.Tbx21* double knockout (dKO) mice exhibited comparable survival to *Il10*^{-/-} mice, suggesting the IFN- γ pathway was dispensable for protection in *Il10*^{-/-} mice

(Fig. 5A). In contrast, *Il10.II22* dKO mice were acutely susceptible to *C. difficile* infection (Fig. 5A). To confirm the dependence of IL-22 signaling for host protection in an IL-10 deficient setting, cohoused C57BL/6 or *Il10*^{HET} mice, *Il10*^{-/-}, *Il22*^{-/-}, *Il10.II22* dKO, and *Il10r2*^{-/-} mice (IL-10R2 is the shared receptor subunit necessary for both IL-10 and IL-22 signaling) were pre-treated with antibiotics and infected with *C. difficile*. Genetic ablation of IL-22 signaling in an IL-10-deficient setting (*Il10.II22* dKO and *Il10r2*^{-/-} mice) led to significantly increased disease morbidity at day 2 p.i. (Fig. 5B), and mortality compared to *Il10*^{-/-} mice (Fig. 5C). Collectively, these data support the conclusion that loss of IL-10 signaling leads to activation of IL-22 dependent host defense mechanisms that limit *C. difficile* pathogenesis.

Discussion

C. difficile infection induces a robust innate inflammatory response that has been extensively studied in the context of pathogenesis. Here, we employed *Il10*^{-/-} mice to decouple constitutive intestinal inflammation from *C. difficile* infection-induced inflammation and determine their respective roles in pathogen defense. Collectively, our data support the conclusion that the absence of IL-10 signaling elevates host defenses prior to infection leading to reduced *C. difficile* pathogenesis in an IL-22 dependent manner. These results implicate a novel and deleterious role for IL-10 in dampening the IL-22 response during enteric *C. difficile* infection.

Previous work by Kim *et al.* assessed IL-10 in the context of *C. difficile* infection and observed severe histopathology in *C. difficile* infected *Il10*^{-/-} mice infected at day 7 p.i. compared to cohoused C57BL/6 mice that developed mild *C. difficile* disease (10-15% weight loss; 100% survival in wild-type mice)⁵¹. The data in this report complements this finding and investigates the role of IL-10 in the acute response to severe *C. difficile* infection (20-30% weight loss; 25-50% survival in C57BL/6 mice). Together, these studies support a model where basal immune activation prior to infection can limit severe acute pathogenesis. However, prolonged *Il10*

deficiency during a milder form of disease tips the balance toward inflammation-driven tissue immunopathology.

Despite the protective capacity of intestinal inflammation reported in this study in the context of *Il10* deficiency, expression of proinflammatory molecules does not uniformly limit *C. difficile* disease. Notably, *Il10*^{-/-} mice are also a widely used model of inflammatory bowel disease (IBD), a well-appreciated risk factor for *C. difficile* disease^{8,52}. Due to its multifactorial nature, however, clinical reports that link IBD to *C. difficile* are not able to differentiate what features of IBD drive increased *C. difficile* disease severity⁵². Research investigating the connection between IBD and *C. difficile* has employed mice treated with dextran sodium sulfate (DSS), a model of chemically-induced colitis, to disentangle the role of proinflammatory immune components in pathogenesis. DSS-treated mice exhibit increased susceptibility to *C. difficile* infection.⁵³ and Saleh *et al.* demonstrated that IL-17 competent CD4⁺ T_H17 cells activated by DSS colitis were sufficient to increase susceptibility to *C. difficile* infection in non-DSS treated mice¹⁶. This work identifies induction of IL-17 during IBD as an inflammatory pathway that promotes *C. difficile* disease.

In the context of the *C. difficile* infection, the IL-23/IL-22/IL-17 axis has a nuanced role in pathogenesis. Genetic ablation of IL-23, a cytokine upstream of IL-17, protects mice from severe *C. difficile* infection¹⁷ while mice deficient in IL-22, which is also directly downstream of IL-23, are acutely susceptible to infection^{13,54}. Further, wild-type mice that receive rIL-22 treatment prior to *C. difficile* challenge are protected from severe infection¹³. Altogether, these observations, along with the results presented here, support a protective role for elevated IL-22 production. At the same time, induction of the IL-23 proinflammatory axis in the absence of IL-22, or in favor of IL-17 production, could drive more severe disease. Multiple IL-22 dependent mechanisms that mediate protection against *C. difficile* infection have been described. Hasegawa *et al.* demonstrated the induction of complement proteins via IL-22 signaling on hepatocytes is required to limit non-*C. difficile* bacterial translocation during severe *C. difficile* infection¹³. In addition to

this systemic role for IL-22, a more recent study demonstrated a role for IL-22 signaling in modulation of intestinal epithelial glycosylation to enable growth of bacterial consumers of succinate, a crucial metabolite for *C. difficile* growth⁵⁵. IL-22 also acts on intestinal epithelial cells to induce expression of genes that encode antimicrobial peptides, including RegIII γ , lipocalin-2, and calprotectin^{56–58}, that limit damage of adherent or mucosal-associated commensal bacteria to the epithelium^{56,57} the latter of which has been associated with host protection against *C. difficile*⁵⁹. In support of this, Gunesequera *et al.* showed that *Il10*^{-/-} mice exhibited enriched expression of these same IL-22 dependent antimicrobial genes, all of which were uniquely lost in *Il10.II22* dKO mice⁶⁰. Thus, elevated IL-22 expression at the time of *C. difficile* infection, as observed in *Il10*^{-/-} mice, positions the host to limit toxin-mediated destruction of the epithelial barrier.

Immune activation in IL-10 deficient hosts disrupts homeostasis at steady-state but is also beneficial in the context of an acute *C. difficile* infection by elevating baseline defense mechanisms prior to infection. This concept of immunological tuning prior to infection has been previously observed with commensal bacteria providing tonic signaling to maintain antiviral defenses in a poised state of readiness to rapidly respond upon viral infection^{61–63}. Thus, the trade-off of constitutive intestinal IL-10 expression is diminished basal activation of immune defense genes and therefore a decreased capacity of the host to respond to pathogen challenge. Understanding the dynamics of this biological balancing act could help develop therapies that selective or transiently targeting the protective components of immune activation in at-risk patients while avoiding deleterious side effects of prolonged inflammation.

Materials and Methods

Mice. Four to six-week old wild-type C57BL/6J, *Il10*^{-/-}, *Tbx21*^{-/-}, *Il10rb*^{-/-} mice were purchased from the Jackson Laboratory. *Il22*^{-/-} mice were provided by R. Flavell (Yale University). All knockout mouse strains were derived on a C57BL/6 background. All mice were bred and maintained in

autoclaved cages under specific pathogen-free conditions at the University of Pennsylvania. All experiments with cohoused C57BL/6 and *Il10^{-/-}* mice were done at Memorial Sloan Kettering Cancer Center. *Il10Il22* dKO and *Il10.Tbx21* dKO mice were generated by breeding *Il10^{-/-}* mice with *Il22^{-/-}* and *Tbx21^{-/-}* mice, respectively. The presence of *Helicobacter spp.*, a bacterial genus sufficient to trigger intestinal inflammation in *Il10^{-/-}* mice by three months of age⁶⁴, was confirmed by PCR in the feces of all breeder *Il10^{-/-}* mice and *Il10^{-/-}*-derived mouse strains. Sex- and age-matched control mice were used in all experiments according to institutional guidelines for animal care. All animal procedures were approved by the Institutional Animal Care and Use Committee of the University of Pennsylvania and Memorial Sloan Kettering Cancer Center.

Antibiotic Pretreatment, *C. difficile* infection , and Mouse Monitoring. Mice were cohoused for 3 weeks prior to antibiotic treatment and then supplemented with metronidazole (0.25 g/l), neomycin (Sigma) (0.25 g/l), and vancomycin (Novaplus) (0.25 g/l) in drinking water for 3 days. One day following cessation of antibiotic water, mice received 200 mg of clindamycin (Sigma) by i.p. injection. Twenty-four hours later, mice received approximately 400 *C. difficile* spores (VPI10463 strain ATCC #43255) via oral gavage. For antibody-mediated blockade experiments, mice received 1 mg of α IL10R1 antibody (clone 1B1.3A, Bio X Cell) or mouse IgG1 isotype control (clone MOPC-21, Bio X Cell) i.p. weekly starting either 3 weeks prior to infection or at day of infection. After infection, mice were monitored and scored for disease severity by four parameters: weight loss (> 95% of initial weight = 0, 95%– 90% initial weight = 1, 90%–80% initial weight = 2, < 80% = 3), surface body temperature (> 32°C = 0, 32°C–30.5°C = 1, 30.5°C–29°C = 2, < 29°C = 3), diarrhea severity (formed pellets = 0, loose pellets = 1, liquid discharge = 2, no pellets/caked to fur = 3), morbidity (score of 1 for each symptoms with a maximum score of 3; ruffled fur, hunched back, lethargy, ocular discharge). Mice that exhibited severe disease, defined as a surface body temperature below 29.5°C or weight loss in excess of 30%, were humanely euthanized.

C. difficile Quantification. Fecal pellets or cecal content were resuspended in deoxygenated PBS, and ten-fold serial dilutions were plated anaerobically at 37°C on brain-heart infusion agar supplemented with yeast extract, L-cysteine, D-cycloserine, cefoxitin, and taurocholic acid (CCBHIS-TA) and colony-forming units (CFUs) were enumerated 24 hours later. Prior to infection, fecal samples from mice were cultured overnight in CCBHIS-TA liquid broth, then serially diluted and grown for 24 hours on CCBHIS-TA plates to ensure that mice did not harbor endogenous *C. difficile* in their microbiota. Supernatants from the cecal or fecal content were obtained after centrifugation for cytotoxicity assays and LCN-2 ELISA (Bethyl Labs).

C. difficile Toxin Cytotoxicity Assay. Vero cells were seeded in 96-well plates at 1×10^4 cells/well and incubated for 24 hours at 37°C in 5% CO₂. Cecal or fecal supernatants were added in ten-fold dilutions to the Vero cells (100 µL/well) and incubated overnight prior to removal, rinsing with PBS, and replacement with fresh media. The presence of *C. difficile* toxins A and B was confirmed by neutralization with antitoxin antisera (Techlab, Blacksburg, VA). The data are expressed as the log₁₀ reciprocal value of the last dilution where cell rounding was observed. Cell morphological changes were observed after 18 hours using a Nikon inverted microscope. The cytopathic effect was determined as rounded cells in comparison to the negative control wells.

16S rRNA sequencing. Cecal content was collected from uninfected mice and mice infected with *C. difficile* at 2 dpi. DNA was extracted using the Qiagen MagAttract Power Microbiome kit DNA/RNA kit (Qiagen, catalog no. 27500-4-EP) and used for rRNA sequencing and *Helicobacter* spp. PCR. Genus-specific PCR was conducted on purified bacterial DNA from feces of *Il10*^{-/-} breeder mice and The V4-V5 region of the 16S rRNA gene was amplified from each sample using the dual indexing sequencing strategy as described previously⁶⁵. Sequencing was done on the

Illumina MiSeq platform. The V4-V5 region of the 16S rRNA gene was sequenced and demultiplexed using the fqgrep tool. Data were imported into QIIME2 (v. 2020.2)⁶⁶ and denoised using the DADA2 plugin⁶⁷. For data in Supplemental Figure 3, the fqgrep tool (<https://github.com/indraniel/fqgrep>) was used to demultiplex the sequences followed by denoising using the DADA2 (v. 1.14.1)⁶⁷ implementation in R (v. 3.6.3)⁶⁸. Due to quality issues on the reverse reads, only the forward reads were used for denoising. Datasets were taxonomically classified in QIIME2 using the q2-feature-classifier⁶⁹ classify-sklearn naïve Bayes classifier with a newly generated classifier against Greengenes 13_8 99% OTU sequences⁷⁰. Phylogenetic trees were generated using mafft⁷¹ and the q2-phylogeny plugin⁷². Data were then imported into R for further analyses with phyloseq (v. 1.30.0)⁷³ and visualization with ggplot2 (v. 3.3.0)⁷⁴. Unweighted UniFrac⁷⁵ dissimilarity was calculated to generate PCoA plots and for creating dendrograms using the hclust function (stats package in R core, v. 3.6.3). Finally, a linear model was built using the lm() and padjust() functions (stats package, v. 3.6.3) as well as the tidyverse package (v. 1.3.0)⁷⁶.

Isolation of lamina propria cells and flow cytometry. Single cell suspensions were obtained from the large intestine lamina propria compartment by longitudinally cutting the large intestine and washing out its contents in PBS. Intestinal tissues were incubated at 37°C under gentle agitation in stripping buffer (PBS, 5 mM EDTA, 1 mM dithiothreitol, 4% FCS, 10µg/mL penicillin/streptomycin) for 10 minutes to remove epithelial cells and then for another 20 minutes for the IEL. The tissue was digested with collagenase IV 1.5 mg/mL (500 U/mL) and DNase (20 µg/mL) in complete media (DMEM supplemented w/ 10% FBS, 10 µg/mL penicillin/streptomycin, 50 µg/mL gentamicin, 10 mM HEPES, 0.5 mM β-mercaptoethanol, 20 µg/mL L-glutamine) for 30 minutes at 37°C under gentle agitation. Supernatants containing the lamina propria fraction were passed through a 100 µm then subsequently 40 µm cell strainer. After counting, cells were plated at 10⁶ cells per well in 96-well round bottom plates and washed twice in 1x PBS before incubating

with a cell viability dye 20 minutes at room temperature (Invitrogen AQUA dye). After Fc blockade (anti-mouse CD16/32 TruStain, BioLegend), cells were stained using a standard flow cytometric staining protocol with fluorescently conjugated antibodies specific to CD3 ϵ , CD5, CD19, CD45, MHC-II, Siglec-F, Ly-6G, Ly6C, CD11b, and CD11c. Stained cells were kept in FACS buffer at 4°C until run. Samples were acquired on an LSR-II flow cytometer (Becton Dickinson). Data were analyzed using FlowJo version 9.9.6 software. Cell populations were calculated from total cells per colon as a percentage of live CD45⁺ cells.

Cytokine and Chemokine Quantification. Cecal tissue was homogenized in tissue extraction buffer with protease inhibitors for 1 minute by bead beating with steel beads. Homogenates were centrifuged at x10,000 rpm for 5 minutes and supernatants were collected and stored at -80° C. Supernatants containing protein were analyzed by Mouse Multiplex Luminex assay (Invitrogen) at the Human Immunology Core at University of Pennsylvania. Concentrations displayed as ng of analyte per gram of cecal tissue.

Tissue RNA Isolation, cDNA Preparation, and qRT-PCR. RNA was isolated from proximal colon tissue using mechanical homogenization and Trizol isolation (Invitrogen) according to the manufacturer's instructions. cDNA was generated using QuantiTect reverse transcriptase (QIAGEN). Quantitative RT-PCR was performed on cDNA using either TaqMan primers and probes or QuantiTect primers in combination with TaqMan PCR Master Mix (ABI) or SYBR Green chemistry and reactions were run on a RT-PCR system (QuantiStudio 6 Flex, Applied Biosystems). Gene expression is displayed as fold increase over antibiotic-pre-treated, uninfected control mice and was normalized to the *Hprt* gene.

Statistical Analysis. Results represent means $\pm$ SEM. Statistical significance was determined by the unpaired t-test and log-rank test for survival curve. Statistical analyses were performed using Prism GraphPad software v6.0 (* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$).

Figure Legend

Figure 1: Genetic ablation of *Il10* results in reduced susceptibility to *C. difficile* infection.

Antibiotic-treated *Il10*^{-/-} and *Il10*^{HET} mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) and monitored daily for disease. (A) Disease score and (B) survival following infection. Data shown are a combination of five independent experiments (*Il10*^{-/-}, n=23; *Il10*^{HET}, n=25). (C) *C. difficile* burden in fecal pellets at day 1 p.i. (D) *C. difficile* burden and (E) *C. difficile* toxin levels in the cecal content at day 2 p.i. ** = $p < 0.01$. Statistical significance was calculated by a log-rank test.

Figure 2: *C. difficile*-infected *Il10*^{-/-} mice and *Il10*^{HET} mice exhibit a similar microbiota composition.

Antibiotic-treated uninfected and *C. difficile* infected *Il10*^{-/-} mice and *Il10*^{HET} mice were sacrificed at day 2 p.i. and cecal content was processed for 16s rRNA bacterial gene profiling. (A) Microbial alpha diversity as determined by the Shannon diversity index. (B) Relative abundance of top 15 bacterial ASVs. Bar plot is displayed at the genus level except for orange bars that represent an ASV aligning to *C. difficile*. (C) Dendrogram representation of intestinal microbial communities using unsupervised hierarchical clustering of unweighted UniFrac distances to identify similarities between samples. (D) Unweighted UniFrac principal coordinate analysis plot of 16S bacterial rRNA ASVs.

Figure 3: *Il10*^{-/-} and *Il10*^{HET} mice exhibit a comparable induction of the innate immune response following acute *C. difficile* infection.

(A) IL-10 protein levels in the cecal tissue homogenates of antibiotic-treated uninfected and day 2 p.i. C57BL/6 mice. (B-H) *Il10*^{-/-} and *Il10*^{HET}

mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) or mock infected and sacrificed two days later. **(B)** LCN-2 protein levels in the cecal supernatants. **(C-E)** Large intestine lamina propria cells were harvested and assessed by flow cytometry for **(C)** neutrophils (CD11b⁺, Ly6G⁺), **(D)** monocyte (CD11b⁺, Ly6C⁺, Ly6G⁻) and **(E)** Eosinophil (SSC^{Hi}, CD11b⁺, Siglec-F⁺) recruitment. **(F)** Fold induction of *Ifng*, *Il22* and **(G)** IFN- γ and IL-22 effector molecules (*Nos2* and *Reg3g*) in the colon at day 2 p.i. relative to uninfected *Il10*^{HET} mice and normalized to *Hprt*. **(H)** IFN- γ , IL-22, and **(I)** type-2 associated cytokine protein levels in the cecal tissue homogenate. Data shown are a combination of two independent experiments (uninfected *Il10*^{-/-}, n=7; uninfected *Il10*^{HET}, n=6; day 2 infected *Il10*^{-/-}, n=8; uninfected *Il10*^{HET}, n=7). Data shown are mean $\pm$ SEM. * = p<0.05. ** = p<0.01. Statistical significance was calculated by an unpaired t-test.

Figure 4: Loss of IL-10 signaling enhances intestinal immune activation prior to infection and decreases susceptibility to acute *C. difficile* infection. Antibiotic-treated uninfected and *Il10*^{-/-} mice and *Il10*^{HET} mice were sacrificed at the day of infection (prior to inoculation). **(A)** Frequency of neutrophils and monocytes in the large intestine lamina propria. FACS plots gated on live, CD45⁺, Non-T, Non-B cells, Siglec-F^{neg}, CD11b⁺ cells. **(B)** Total number of neutrophils and monocytes in the large intestine lamina propria. Data is a combination representative of two independent experiments. *Il10*^{-/-}, n=8; *Il10*^{HET}, n=9. **(C)** Fold induction of type-1 and type-17 associated effector molecules in the colon of antibiotic-treated, uninfected *Il10*^{-/-} mice relative to antibiotic treated uninfected *Il10*^{HET} mice and normalized to *Hprt*. Data is a combination representative of three independent experiments. *Il10*^{-/-}, n=12; *Il10*^{HET}, n=13. Data shown are mean $\pm$ SEM. **(D)** C57BL/6 mice were cohoused with *Il10*^{-/-} mice for two weeks then were administered anti-IL10R1 or isotype control (Rat IgG1) by i.p. injection weekly for three weeks prior to infection or received a single dose of anti-IL10R1 on the day of *C. difficile* infection and

assessed for survival following infection. Data are a combination of two independent experiments (n=8 per group). * = p < 0.05. Statistical significance was calculated by an unpaired t-test or a log-rank test.

Figure 5. IL-22 signaling is required for protection against *C. difficile* infection in *Il10*^{-/-} mice.

(A) Cohoused *Il10*^{-/-}, *Il10.IL22* dKO and *Il10.Tbx21* dKO mice were pre-treated with antibiotics and inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) and assessed for survival following infection. Survival curve is a combination of three independent experiments. (*Il10*^{-/-}, n=7; *Il10.IL22* dKO, n=12; *Il10.Tbx21* dKO, n=14). **(B)** Disease severity at day 2 p.i. and **(C)** survival curve of cohoused C57BL/6 or *Il10*^{HET} (wild-type - WT), *Il10*^{-/-}, *Il10r2*^{-/-}, *Il10*^{-/-}, *IL22*^{-/-}, and *Il10.IL22* dKO mice following *C. difficile* infection. Data shown are a combination of four independent experiments (WT, n=12; *Il10*^{-/-}, n=14; *Il10r2*^{-/-}, n=14; *IL22*^{-/-}, n=16; *Il10.IL22* dKO, n=12).

* = p<0.05. Statistical significance was calculated by an unpaired t-test or a log-rank test.

Supplementary Figure 1: *Il10*^{-/-} mice are less susceptible to *C. difficile* infection compared

to cohoused C57BL/6 mice. (A) *Il10*^{-/-} and C57BL/6 (B6) mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) and assessed for survival following infection. Survival curve is a combination of four independent experiments (*Il10*^{-/-}, n=31; C57BL/6, n=33). **(B)** *C. difficile* burden and **(C)** toxin levels in the cecal content at days 2 and 4 p.i. ** = p<0.01. Statistical significance was calculated by a log-rank test.

Supplementary Figure 2: Identification of individual ASVs that correlate with *C. difficile*-

infected *Il10*^{-/-} mice and *Il10*^{HET} mice. (A) Linear modeling of ASV abundances in *Il10*^{HET} and *Il10*^{-/-} cecal microbiotas fail to identify differences in microbiota compositions. **(A)** Abundance of top 3 ASVs correlating significantly with experimental groups were plotted. **(B)** Model

comparisons for experimental groups show significantly different ASV abundances that correlate with group phenotype. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

Supplementary Figure 3: Cohousing *Il10^{-/-}* mice with C57BL/6 mice assimilates their microbiota prior to infection. Fecal pellets were collected from *Il10^{-/-}* and wild-type mice starting prior to cohousing (day -64 p.i.), following cohousing (day -55, -47 p.i.), the start of antibiotic treatment (day -6 p.i.), and the day of infection (day 0 p.i.). Fecal pellets were processed for 16S rRNA bacterial gene profiling. **(A)** Unweighted UniFrac principal coordinate analysis plot of 16S bacterial rRNA ASVs. **(B)** Relative abundance of top 15 bacterial ASVs. **(C)** Dendrogram representation of intestinal microbial communities using unsupervised hierarchical clustering of unweighted UniFrac distances to identify similarities between samples. **(D)** Microbial alpha diversity as determined by the Shannon diversity index. **(E)** LEfSe analysis identifying significantly differentially abundance ASVs prior to cohousing (day -64 p.i.), prior to antibiotics (day -6 p.i.), and at the day of infection (day 0 p.i.). ** = $p < 0.01$.

Supplementary Figure 4: *Il10^{-/-}* and *Il10^{HET}* mice exhibit comparable granulocyte infiltration induction of proinflammatory cytokines and chemokines following acute *C. difficile* infection. *Il10^{-/-}* and *Il10^{HET}* mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) or mock infected and sacrificed two days later. **(A-B)** Flow cytometry gating strategy identifying frequency of **(A)** eosinophils, **(B)** neutrophils, monocytes in the large intestine lamina propria of day 2 p.i. *Il10^{-/-}* and *Il10^{HET}* mice. First FACS plot is gated on live, CD45⁺ cells. **(C)** Proinflammatory cytokines and **(D)** chemokines protein levels in the cecal tissue homogenate. Data shown are a combination of two independent experiments (uninfected *Il10^{-/-}*, $n=7$; uninfected *Il10^{HET}*, $n=6$; day 2 infected *Il10^{-/-}*, $n=8$; uninfected *Il10^{HET}*, $n=7$). Data shown are mean $\pm$ SEM.

Supplemental Table 1. PERMANOVA analysis of unweighted UniFrac distances between the intestinal microbial communities of antibiotic-treated uninfected and *C. difficile* infected *Il10^{-/-}* and *Il10^{HET}* mice at day 2 p.i. Statistical tests performed on data displayed in Figure 2.

Supplemental Table 2. PERMANOVA analysis of unweighted UniFrac distances between the intestinal microbial communities of *Il10^{-/-}* and C57BL/6 mice starting prior to cohousing (day -64 p.i.), following cohousing (day -55, -47 p.i.), the start of antibiotic treatment (day -6 p.i.), and the day of infection (day 0 p.i.). Statistical tests performed on data displayed in Supplemental Figure 3.

Acknowledgements

We thank the members of the Abt lab for helpful discussion and critical reading of the manuscript. We would also like to thank L. Mattei of the Penn CHOP Microbiome Core and L. Lang of the Lucille Castori Center for Microbes, Inflammation and Cancer for technical expertise in high throughput sequencing and E. Pamer for mice strains. Finally, we thank L. Zhao and R. Shimol of the Penn Human Immunology Core for technical expertise with Luminex assays. This research was supported by the NIH (R00 AI125786 to M.C.A and T32 AI141393 to E.S.C.).

References

1. Lessa, F. C. *et al.* Burden of Clostridium Difficile Infection in the United States. *N. Engl. J. Med.* **372**, 825–834 (2015).
2. Ofori, E. *et al.* Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. *J. Hosp. Infect.* (2018). doi:10.1016/j.jhin.2018.01.015
3. *Clostridioides difficile*. CDC's 2019 Antibiotic Resistant Threats Report (2019). doi:10.1016/j.tim.2018.09.004
4. Guh, A. Y. *et al.* Trends in U.S. Burden of clostridioides difficile infection and outcomes. *N. Engl. J. Med.* **382**, 1320–1330 (2020).
5. Collins, J. *et al.* Dietary trehalose enhances virulence of epidemic Clostridium difficile. *Nature* **553**, 291–294 (2018).
6. Brown, A. W. W. & Wilson, R. B. Clostridium difficile colitis and zoonotic origins—a narrative review. *Gastroenterol. Rep.* **6**, 157–166 (2018).
7. Khanafer, N. *et al.* Factors predictive of severe Clostridium difficile infection depend on the definition used. *Anaerobe* **37**, 43–48 (2016).
8. Ananthakrishnan, A. N., McGinley, E. L. & Binion, D. G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. *Gut* **57**, 205–210 (2008).
9. Sun, X. & Hirota, S. A. The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection. *Mol. Immunol.* **63**, 193–202 (2015).
10. Buonomo, E. L. & Petri, W. A. The microbiota and immune response during Clostridium difficile infection. *Anaerobe* **41**, 79–84 (2016).
11. Péchiné, S. & Collignon, A. Immune responses induced by Clostridium difficile. *Anaerobe* **41**, 68–78 (2016).
12. Hasegawa, M. *et al.* Nucleotide-Binding Oligomerization Domain 1 Mediates Recognition of Clostridium difficile and Induces Neutrophil Recruitment and Protection against the Pathogen. *J. Immunol.* **186**, 4872–4880 (2011).
13. Hasegawa, M. *et al.* Interleukin-22 Regulates the Complement System to Promote Resistance against Pathobionts after Pathogen-Induced Intestinal Damage. *Immunity* **41**, 620–632 (2014).
14. Abt, M. C. *et al.* Innate immune defenses mediated by two ilc subsets are critical for protection against acute clostridium difficile infection. *Cell Host Microbe* **18**, 27–37 (2015).
15. Frisbee, A. L. *et al.* IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. *Nat. Commun.* **10**, 2712 (2019).

16. Saleh, M. M. *et al.* Colitis-Induced Th17 Cells Increase the Risk for Severe Subsequent Clostridium difficile Infection. *Cell Host Microbe* 1–10 (2019). doi:10.1016/j.chom.2019.03.003
17. Buonomo, E. L. *et al.* Role of interleukin 23 signaling in clostridium difficile colitis. *J. Infect. Dis.* **208**, 917–920 (2013).
18. Jose, S. *et al.* Neutralization of macrophage migration inhibitory factor improves host survival after Clostridium difficile infection. *Anaerobe* **53**, 56–63 (2018).
19. Steiner, T. S., Flores, C. A., Pizarro, T. T. & Guerrant, R. L. Fecal lactoferrin, interleukin-1 β , and interleukin-8 are elevated in patients with severe Clostridium difficile colitis. *Clin. Diagn. Lab. Immunol.* **4**, 719–722 (1997).
20. Yu, H. *et al.* Cytokines Are Markers of the Clostridium difficile-induced Inflammatory Response and Predict Disease Severity. *Clin. vaccine Immunol.* **24**, 1–11 (2017).
21. El Feghaly, R. E. *et al.* Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in clostridium difficile infection. *Clin. Infect. Dis.* **56**, 1713–1721 (2013).
22. Ouyang, W., Rutz, S., Crellin, N. K., Valdez, P. A. & Hymowitz, S. G. Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease. *Annu. Rev. Immunol.* **29**, 71–109 (2011).
23. Fillatreau, S., Editors, A. O. G. & Freiburg, L. *Interleukin-10 in Health and Disease*. **380**, (2014).
24. Shouval, D. S. *et al.* *Interleukin 10 receptor signaling: Master regulator of intestinal mucosal homeostasis in mice and humans. Advances in Immunology* **122**, (Elsevier Inc., 2014).
25. Kühn, R., Löhler, J., Rennick, D., Rajewsky, K. & Müller, W. Interleukin-10-deficient mice develop chronic enterocolitis. *Cell* **75**, 263–274 (1993).
26. Sellon, R. K. *et al.* Resident Enteric Bacteria Are Necessary for Development of Spontaneous Colitis and Immune System Activation in Interleukin-10-Deficient Mice. *Infect. Immun.* **66**, 5224–5231 (1998).
27. Kullberg, M. C. *et al.* IL-23 plays a key role in Helicobacter hepaticus –induced T cell–dependent colitis . *J. Exp. Med.* **203**, 2485–2494 (2006).
28. Keubler, L. M., Buettner, M., Häger, C. & Bleich, A. A multihit model: Colitis lessons from the interleukin-10-deficient mouse. *Inflamm. Bowel Dis.* **21**, 1967–1975 (2015).
29. Vazquez-Torres, A., Jones-Carson, J., Wagner, R. D., Warner, T. & Balish, E. Early resistance of interleukin-10 knockout mice to acute systemic candidiasis. *Infect. Immun.* **67**, 670–674 (1999).
30. Sewnath, M. E. *et al.* IL-10-Deficient Mice Demonstrate Multiple Organ Failure and Increased Mortality During Escherichia coli Peritonitis Despite an Accelerated Bacterial Clearance. *J. Immunol.* **166**, 6323–6331 (2014).
31. Arai, T. *et al.* Effects of in vivo administration of anti-IL-10 monoclonal antibody on the host defence mechanism against murine Salmonella infection. *Immunology* **85**, 381–388 (1995).

32. Villegas, E. N. *et al.* Blockade of costimulation prevents infection-induced immunopathology in interleukin-10-deficient mice. *Infect. Immun.* **68**, 2837–2844 (2000).
33. Dann, S. M. *et al.* Attenuation of intestinal inflammation in interleukin-10-deficient mice infected with *Citrobacter rodentium*. *Infect. Immun.* **82**, 1949–1958 (2014).
34. Leber, A. *et al.* Systems modeling of interactions between mucosal immunity and the gut microbiome during *Clostridium difficile* infection. *PLoS One* **10**, 1–19 (2015).
35. Peñaloza, H. F. *et al.* Opposing roles of IL-10 in acute bacterial infection. *Cytokine Growth Factor Rev.* **32**, 17–30 (2016).
36. Grainger, J. R. *et al.* Inflammatory monocytes regulate pathologic responses to commensals during acute gastrointestinal infection. *Nat. Med.* **19**, 713–721 (2013).
37. Brooks, D. G. *et al.* Interleukin-10 determines viral clearance or persistence in vivo. *Nat. Med. Vol.* **12**, (2006).
38. Ryan, A. *et al.* A role for TLR4 in *clostridium difficile* infection and the recognition of surface layer proteins. *PLoS Pathog.* **7**, e1002076 (2011).
39. Jafari, N. V. *et al.* *Clostridium difficile* Modulates Host Innate Immunity via Toxin-Independent and Dependent Mechanism(s). *PLoS One* **8**, 1–10 (2013).
40. Lynch, M. *et al.* Surface layer proteins from virulent *Clostridium difficile* ribotypes exhibit signatures of positive selection with consequences for innate immune response. *BMC Evol. Biol.* **17**, 90 (2017).
41. Rutz, S., Ouyang, W., Rutz, S. & Ouyang, W. Regulation of Cytokine Gene Expression in Immunity and Diseases. *Adv. Exp. Med. Biol.* **941**, (2016).
42. Snapper, S. B., McInnis, C. M., Conaway, E. A., de Oliveira, D. C. & Horwitz, B. H. Inhibition of Inflammatory Gene Transcription by IL-10 Is Associated with Rapid Suppression of Lipopolysaccharide-Induced Enhancer Activation. *J. Immunol.* **198**, 2906–2915 (2017).
43. Abt, M. C., McKenney, P. T. & Pamer, E. G. *Clostridium difficile* colitis: Pathogenesis and host defence. *Nat. Rev. Microbiol.* **14**, 609–620 (2016).
44. Jarchum, I., Liu, M., Shi, C., Equinda, M. & Pamer, E. G. Critical role for myd88-Mediated Neutrophil recruitment during *Clostridium difficile* colitis. *Infect. Immun.* **80**, 2989–2996 (2012).
45. Buonomo, E. L. *et al.* Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during *Clostridium difficile* Infection. *Cell Rep.* **16**, 432–443 (2016).
46. Chassaing, B. *et al.* Fecal Lipocalin 2, a Sensitive and Broadly Dynamic Non-Invasive Biomarker for Intestinal Inflammation. *PLoS One* **7**, 3–10 (2012).
47. Gunasekera, D. C. *et al.* The development of colitis in Il10^{-/-} mice is dependent on IL-22. *Mucosal Immunol.*

- (2020). doi:10.1038/s41385-019-0252-3
48. Jarry, A. *et al.* Mucosal IL-10 and TGF- β play crucial roles in preventing LPS-driven, IFN- γ -mediated epithelial damage in human colon explants. *J. Clin. Invest.* **118**, 1132–1142 (2008).
49. Proinflammatory Role of Monocyte-Derived CX3CR1^{int} Macrophages in Helicobacter hepaticus-Induced Colitis Calum. *Infect. Immun.* **86**, e00579-17 (2018).
50. Young, V. B. *et al.* Tryptophan Catabolism Restricts IFN- γ -Expressing Neutrophils and Clostridium difficile Immunopathology. *J. Immunol.* **193**, 807–816 (2014).
51. Kim, M. N. *et al.* Clostridium difficile infection aggravates colitis in interleukin 10-deficient mice. *World J. Gastroenterol.* **20**, 17084–17091 (2014).
52. Zhang, T. *et al.* Clostridium Difficile Infection Worsen Outcome of Hospitalized Patients with Inflammatory Bowel Disease. *Sci. Rep.* **6**, 1–8 (2016).
53. Zhou, F. *et al.* Mice with inflammatory bowel disease are susceptible to clostridium difficile infection with severe disease outcomes. *Inflamm. Bowel Dis.* **24**, 573–582 (2018).
54. Bernshtein, B. *et al.* IL-23-producing IL-10R α -deficient gut macrophages elicit an IL-22-driven proinflammatory epithelial cell response. *Sci. Immunol.* **4**, 1–15 (2019).
55. Nagao-kitamoto, H. *et al.* Interleukin-22-mediated host glycosylation prevents Clostridioides difficile infection by modulating the metabolic activity of the gut microbiota. *Nat. Med.* (2020).
56. Zheng, Y. *et al.* Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat. Med.* **14**, 282–289 (2008).
57. Behnsen, J. *et al.* The Cytokine IL-22 Promotes Pathogen Colonization by Suppressing Related Commensal Bacteria. *Immunity* **40**, 262–273 (2014).
58. Couturier-Maillard, A. *et al.* Interleukin-22-deficiency and microbiota contribute to the exacerbation of Toxoplasma gondii-induced intestinal inflammation article. *Mucosal Immunol.* **11**, 1181–1190 (2018).
59. Zackular, J. P. *et al.* Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. *Nat. Med.* **22**, 1330–1334 (2016).
60. Gunasekera, D. C. *et al.* The development of colitis in Il10 $-/-$ mice is dependent on IL-22. *Mucosal Immunol.* (2020). doi:10.1038/s41385-019-0252-3
61. Steed, A. L. *et al.* The microbial metabolite desaminotyrosine protects from influenza through type I interferon. *Science (80-.).* **502**, 498–502 (2017).
62. Ganai, S. C. *et al.* Priming of Natural Killer Cells by Nonmucosal Mononuclear Phagocytes Requires Instructive Signals from Commensal Microbiota. *Immunity* **37**, 171–186 (2012).

63. Abt, M. C. *et al.* Commensal Bacteria Calibrate the Activation Threshold of Innate Antiviral Immunity Michael. *Immunity* **37**, 158–170 (2012).
64. Kullberg, M. C. *et al.* Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12-and gamma interferon- dependent mechanism. *Infect. Immun.* **66**, 5157–5166 (1998).
65. Kozich, J. J., Westcott, S. L., Baxter, N. T., Highlander, S. K. & Schloss, P. D. Development of a dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the miseq illumina sequencing platform. *Appl. Environ. Microbiol.* **79**, 5112–5120 (2013).
66. Bolyen, E. *et al.* Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. *Nat. Biotechnol.* **37**, 852–857 (2019).
67. Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina amplicon data. *Nat. Methods* **13**, 581–583 (2016).
68. Team, R. C. R: A language and environment for statistical computing. *R Found. Stat. Comput.* 1–16 (2020). doi:10.1108/eb003648
69. Bokulich, N. A. *et al.* q2-sample-classifier: machine-learning tools for microbiome classification and regression. *J. open source Softw.* **3**, (2018).
70. McDonald, D. *et al.* An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *ISME J.* **6**, 610–618 (2012).
71. Katoh, K., Misawa, K., Kuma, K. I. & Miyata, T. MAFFT: A novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res.* **30**, 3059–3066 (2002).
72. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 - Approximately maximum-likelihood trees for large alignments. *PLoS One* **5**, (2010).
73. McMurdie, P. J. & Holmes, S. Phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. *PLoS One* **8**, (2013).
74. Wickham, H. *ggplot2 – Elegant Graphics for Data Analysis.* Springer-Verlag (2016). doi:10.18637/jss.v077.b02
75. Lozupone, C. & Knight, R. UniFrac: A new phylogenetic method for comparing microbial communities. *Appl. Environ. Microbiol.* **71**, 8228–8235 (2005).
76. Wickham, H. *et al.* Welcome to the Tidyverse. *J. Open Source Softw.* **4**, 1686 (2019).

Figure 1

Figure 1: Genetic ablation of *Il10* results in reduced susceptibility to *C. difficile* infection.

Il10^{-/-} and *Il10*^{HET} mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) and monitored daily for disease. (A) Disease score and (B) survival following infection. Data shown are a combination of five independent experiments (*Il10*^{-/-}, n=23; *Il10*^{HET}, n=25). (C) *C. difficile* burden in fecal pellets at day 1 p.i.. (D) *C. difficile* burden and (E) *C. difficile* toxin levels in the cecal content at day 2 p.i. ** = p<0.01. Statistical significance was calculated by a Log-rank test.

Figure 2

Figure 2: *C. difficile*-infected *II10*^{-/-} mice and *II10*HET mice exhibit a similar microbiome composition. ABX-treated uninfected and *C. difficile* infected *II10*^{-/-} mice and *II10*HET mice were sacrificed at day 2 p.i. and cecal content processed for 16S rRNA bacterial gene profiling. (A) Microbial alpha diversity as determined by the Shannon diversity index. (B) Relative abundance of top 15 bacterial ASVs. Bar plot is displayed at the genus level except for orange bars that represent an ASV aligning to *C. difficile*. (C) Dendrogram representation of intestinal microbial communities using unsupervised hierarchical clustering of unweighted UniFrac distances to identify similarities between samples. (D) Unweighted UniFrac principal coordinate analysis plot of 16S bacterial rRNA ASVs.

Figure 3

Figure 3: IL10^{-/-} and IL10^{HET} mice exhibit a comparable induction of the innate immune response following acute *C. difficile* infection. (A) IL-10 protein levels in the cecal tissue homogenates of antibiotic-treated uninfected and day 2 p.i. C57BL/6 mice. (B-H) IL10^{-/-} and IL10^{HET} mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) or mock infected and sacrificed two days later. (B) LCN-2 protein levels in the cecal supernatants. (C-E) Large intestine lamina propria cells were harvested and assessed by flow cytometry for (C) neutrophils (CD11b+, Ly6G+), (D) monocyte (CD11b+, Ly6C+, Ly6G-) and (E) Eosinophil (SSChi, CD11b+, Siglec-F+) recruitment. (F) Fold induction of *lfn*, *Il22* and (G) IFN- γ and IL-22 effector molecules in the colon at day 2 p.i. relative to uninfected IL10^{HET} mice and normalized to Hprt. (H) IFN- γ , IL-22, and (I) type-2 associated cytokine protein levels in the cecal tissue homogenate. Data shown are a combination of two independent experiments (uninfected IL10^{-/-}, n=7; uninfected IL10^{HET}, n=6; day 2 infected IL10^{-/-}, n=8; uninfected IL10^{HET}, n=7). Data shown are mean $\pm$ SEM. * = p<0.05. ** = p<0.01. Statistical significance was calculated by an unpaired t-test.

Figure 4

Figure 4: Loss of IL-10 signaling enhances intestinal immune activation prior to infection and decreases susceptibility to acute *C. difficile* infection. Antibiotic-treated uninfected and *II10*^{-/-} mice and *II10*^{HET} mice were sacrificed at the day of infection (prior to inoculation). (A) Frequency of neutrophils and monocytes in the large intestine lamina propria. FACS plots gated on live, CD45⁺, Non-T, Non-B cells, Siglec-F⁺eg, CD11b⁺ cells. (B) Total number of neutrophils, monocytes and eosinophils in the large intestine lamina propria. Data is a combination representative of two independent experiments. *II10*^{-/-}, n=8; *II10*^{HET}, n=9. (C) Fold induction of type-1 and type-17 associated effector molecules in the colon of antibiotic-treated, uninfected *II10*^{-/-} mice relative to antibiotic-treated uninfected *II10*^{HET} mice and normalized to Hprt. Data is a combination representative of three independent experiments. *II10*^{-/-}, n=12; *II10*^{HET}, n=13. Data shown are mean $\pm$ SEM. (D) C57BL/6 mice were cohoused with *II10*^{-/-} mice for two weeks then were administered anti-IL10R1 or isotype control (Rat IgG1) by i.p. injection weekly for three weeks prior to infection or received a single dose of anti-IL10R1 on the day of *C. difficile* infection and assessed for survival following infection. Data are a combination of two independent experiments (n=8 per group). * = p < 0.05. Statistical significance was calculated by an unpaired t-test or a log-rank test.

Figure 5

Figure 5. IL-22 signaling is required for protection against *C. difficile* infection in *Il10*^{-/-} mice. (A) Cohoused wild-type *Il10*^{-/-}, *Il10.II22* dKO and *Il10.Tbx21* dKO mice were inoculated with approximately 400 spores of *C. difficile* (VPI 10463 strain) and assessed for survival following infection. Survival curve is a combination of three independent experiments. (*Il10*^{-/-}, n=7; *Il10.II22* dKO, n=12; *Il10.Tbx21* dKO, n=14). (B) Disease severity at day 2 p.i. and (C) survival curve of cohoused B6 or *Il10*HET, *Il10*^{-/-}, *Il10r2*^{-/-}, *Il10*^{-/-}, and *Il10.II22* dKO mice following *C. difficile* infection. Data shown are a combination of four independent experiments (B6, n=12; *Il10*^{-/-}, n=14; *Il10r2*^{-/-}, n=14; *Il22*^{-/-}, n=16; *Il10.II22* dKO, n=12). * = p<0.05. Statistical significance was calculated by an unpaired t-test or a log-rank test.